ADGRL3 and metastatic colorectal cancer: LPHN3, a stage-2 salient gene, is targeted in four clinical trials aimed against metastatic colorectal cancer, to explore possible therapeutic efficacy in thwarting cancer progression prior to irreversible outcomes.